Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Clinical Trials Related to Osimertinib
Related studies linked through entity extraction aliases.
Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Osimertinib (AZD9291) in First-line Locally Advanced or Metastatic NSCLC Patients With EGFR and EGFR T790M
- Status
- COMPLETED
- Phase
- PHASE2
Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Osimertinib in First and Second Line Treatment of NSCLC Harboring EGFR Mutations From Circulating Tumor DNA
- Status
- COMPLETED
- Phase
- PHASE2
Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib
- Status
- COMPLETED
- Phase
- PHASE2
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1